Due to the efficacy of GLP-1 agonists in improving metabolic and reproductive endocrine dysfunction in PCOS, they are considered promising therapeutic agents for this condition (Figure 4; Babar et al., 2023). This evidence concerns the gene GLP1R and polycystic ovary syndrome.